Intellia Therapeutics Inc (NTLA) 2021 Q1 法說會逐字稿

Good morning. My name is Eden, and I'll be your conference operator today. Welcome to the Intellia Therapeutics First Quarter 2021 Financial Results Conference Call. (Operator Instructions) This conference is being recorded at the company's request and will be available on the company's website following the end of the call.

I will now turn the conference over to Lina Li, Director of Investor Relations at Intellia. Please proceed.

Thank you, operator, and good morning, everyone. Welcome to Intellia's First Quarter 2021 Earnings Call. Earlier today, the company issued a press release outlining the company's progress this quarter as well as topics for further discussion on today's call. This release can be found on the Investors & Media section of Intellia's website at intelliatx.com. This call is being broadcast live, and a replay will also be archived on the company's website.

At this time, I would like to take a minute to remind listeners that during this call, Intellia management may make certain forward-looking statements and ask that you refer to our SEC filings available at sec.gov for a discussion of potential risks and uncertainties. All information presented on this call is current as of today, and Intellia undertakes no duty to update this information unless required by law.

Joining me on the call today are Dr. John Leonard, Chief Executive Officer; Dr. David Lebwohl, Chief Medical Officer; Dr. Laura Sepp-Lorenzino, Chief Scientific Officer; and Glenn Goddard, Chief Financial Officer. For today's call, John will start with the company's first quarter and recent business highlights, followed by David, who will provide an update on our NTLA-2001 clinical efforts. Laura will then recap the company's R&D progress, followed by Glenn's review of Intellia's financial results for the quarter. John will then make some closing remarks, and we will open the call for Q&A.

With that, let me turn the call over to our CEO. John?

Thank you, Lina, and good morning, everyone. We're happy to provide an update on recent progress against our core priorities for this year and a view forward to our key upcoming catalysts.

At Intellia, we're committed to developing curative, genome-editing treatments to transform the lives of individuals with severe diseases, and we're proud to be at the forefront of genomic medicine. Our deep scientific, technical and clinical development expertise and robust intellectual property portfolio position us to transform the broad therapeutic potential of CRISPR/Cas9 into new classes of revolutionary medicines.

Our leading platform supports a full-spectrum strategy, which deploys differentiated, modular solutions across in vivo and ex vivo therapeutic applications. For genetic disease, we utilize our in vivo approach, leveraging a lipid nanoparticle-based delivery system to selectively knock out disease-causing genes or precisely insert genes to produce normal proteins. Our ex vivo T-cell receptor, or TCR-based approach, is designed to produce a homogeneous, robust cell product that epitomizes the patient's own natural immune system to eliminate cancer cells. Across these efforts, we have generated a broad pipeline, including emerging clinical candidates and an expansive research stage portfolio following a rapid and reproducible development path.

The first quarter was a productive one for Intellia as we continue to make headway across these efforts. We were pleased to receive the European Union's orphan drug designation for NTLA-2001, demonstrating regulators' appreciation of the potential significant benefit of NTLA-2001 in the treatment of ATTR patients for whom there is no cure.

Additionally, we presented key preclinical data expanding our modular capabilities in new directions. In March, we introduced our proprietary base-editing technology for enhanced cell engineering. In a separate presentation, we showed proof of concept for systemic in vivo editing in bone marrow. Platform innovations such as these lay an important foundation for Intellia's continued pipeline growth and the advancement of the next wave of genomic medicines.

Finally, we were pleased to welcome Dr. Georgia Keresty, who joins our Board with more than 35 years of pharmaceutical industry experience, including as a scientific and operational leader across stages of clinical development and commercial manufacturing.

Our progress on these first quarter and upcoming milestones provides us the opportunity to advance not only our core priorities for 2021 but our long-term vision for Intellia. We continued the evaluation of the clinical profile of NTLA-2001 both as a potentially curative treatment option for ATTR patients and as validation of our nonviral in vivo delivery platform. In the middle of this year, we anticipate reporting our first clinical data with an interim look at our Phase I study of NTLA-2001, the first systemically delivered CRISPR-based therapy dosed in patients.

In addition, we plan to submit 2 first-in-human regulatory filings to advance our lead engineered TCR T-cell therapy, NTLA-5001, for AML; and our second in vivo knock-out candidate, NTLA-2002, for HAE. And we remain on track to nominate at least one new development candidate from our research efforts by the end of the year.

With key catalysts upcoming and a strong financial foundation, we are positioned to invest the resources and energy necessary to advance our pipeline, expand our platform capabilities and deliver on our mission for patients.

With that introduction, I'll hand the call over to our Chief Medical Officer, David Lebwohl, who will provide an update on our progress in the clinic with NTLA-2001. David?

Thanks, John, and good morning, everyone. I'll start with a bit of background on ATTR and on NTLA-2001.

Transthyretin amyloidosis, or ATTR, is a rare, progressive and fatal disease caused by the buildup of TTR protein in multiple organs. People living with the disease can have either the hereditary or wild-type form of ATTR, which results in a diverse range of disease manifestations, the most frequent being polyneuropathy and cardiomyopathy. Globally, there are an estimated 50,000 people with hereditary ATTR and between 200,000 and 500,000 with wild-type ATTR.

Intellia's candidate, 2001, applies our in vivo lipid nanoparticle delivery technology to knock out the TTR gene in the liver, which is the source of circulating wild-type and mutant TTR protein, therefore, reducing amyloid deposition. Based on our robust preclinical data, which shows long-lasting TTR reduction of greater than 95% in nonhuman primates after a single dose, we believe 2001 offers the possibility of halting and reversing all forms of the disease with potent, lifelong reduction of serum TTR following a single dose.

In March, the European Commission granted orphan drug designation to 2001. As a reminder, this designation provides regulatory, financial and commercial incentives to develop therapies for rare diseases defined as having a prevalence of less than 5,000 and 10,000 people in the European Union. This is meaningful as it not only reflects 2001's potential to deliver significant benefit over existing treatment for ATTR but also the unmet need that remains in this population.

We view this as an important acknowledgment that regulators recognize the benefit of a potential single-dose treatment in indications like ATTR, even when product therapies exist in the market. Importantly, this is in line with our conviction of this program as well as feedback from leading investigators who are enthusiastic about the value 2001 would offer patients and our health care system.

As you may recall, our first-in-human trial is an open-label, multi-center, 2-part study, evaluating 2001 in adults with the hereditary form of ATTR and peripheral nerve damage. The study will enroll up to 38 patients and consist of a single, ascending-dose phase in Part 1 and, following the identification of an optimal dose, a single-dose expansion cohort in Part 2. The trial's primary objectives are to assess the safety, tolerability, pharmacokinetic and pharmacodynamics of 2001, which will include the measurement of serum TTR levels following a single intravenous infusion.

The secondary objectives are to evaluate the efficacy of 2001 on clinical measure of neurologic function in hATTR-PN patients. Once we have established the safety and the optimal dose, our goal is to expand this study and rapidly move to pivotal studies in which we aim to enroll both polyneuropathy and cardiomyopathy patients.

By way of clinical update, we continue to enroll patients across global sites and expect to share interim results from the ongoing single-ascending dose portion of the study at a scientific or medical meeting in mid-2021. These results will offer a preliminary view of the safety and activity profile of 2001 as we progress towards identifying the optimal biological dose. We believe our interim results will establish clinical proof of concept for a modular LNP delivery platform, an important milestone for Intellia, while demonstrating to the field at large the potential for systemic in vivo genome editing in treating life-threatening diseases. We are excited to learn how our ability to edit in vivo translates from our observations preclinically into humans and look forward to sharing interim results mid this year.

And with that, I'll turn this over to our Chief Scientific Officer, Laura Sepp-Lorenzino, for updates on our 2 additional development candidates, 2002 and 5001, and across our R&D efforts.

Thanks, David. I'll begin with our second in vivo knock-out candidate, NTLA-2002, in development for the treatment of hereditary angioedema, or HAE.

HAE patients experience recurring, unpredictable and painful attacks of swelling across multiple tissues. While there are approved acute and prophylactic therapies for HAE, the treatment burden on patients remain significant. We believe there is additional opportunity for a therapy that not only further reduces frequency and intensity of attacks but which may prevent and eliminate them altogether.

To that end, we're applying our modular LNP delivery system to NTLA-2002 to knock out the KLKB1 in the liver to permanently reduce plasma kallikrein protein and activity. This approach is expected to provide continuous suppression of kallikrein activity and eliminate the significant treatment burden associated with currently available therapies for HAE patients.

In March, we presented preclinical results at the American Academy of Allergy, Asthma & Immunology Annual Meeting, demonstrating NTLA-2002 achieved greater reductions in serum kallikrein protein levels and activity as compared to published results of the current standard of care for HAE. These reductions of up to approximately 90% were sustained for over 17 months following a single dose in an ongoing nonhuman primate study of our cyno-specific LNP formulation for NTLA-2002.

In addition, we presented data from the humanized KLKB1 mouse model of bradykinin-mediated vascular permeability, establishing that a single administration of NTLA-2002 prevented captopril-induced vascular leakage and, therefore, is expected to prevent HAE attacks.

We continue to make steady progress with IND-enabling activities, and we expect to submit an IND or equivalent application for NTLA-2002 in the second half of this year. We're leveraging insights from NTLA-2001 and, therefore, anticipate being able to start NTLA-2002 at a higher dose for our first-in-human study, which will evaluate safety, tolerability and measures of activity, including levels of kallikrein knockdown.

I will now turn to our ex vivo efforts. Here, we're using CRISPR/Cas9 as a tool to create engineered cell therapies. Similar to our efforts in vivo, our proprietary approach to cell engineering underpins a modular platform with versatility to mix and match cell types, targeting modalities and ability to introduce the edits necessary for eliciting the desired pharmacology. Regardless of solutions, we're achieving highly efficient sequential editing with high yield, optimal cell performance and scalable manufacturing.

Our lead program, NTLA-5001, is a potential best-in-class engineered T-cell therapy designed to treat all genetic subtypes of AML. This investigational candidate is an autologous T-cell receptor, or TCR, T-cell therapy, targeting the Wilms' Tumor 1 antigen. NTLA-5001 utilizes our proprietary cell engineering process, which is able to precisely edit and replace patients' T-cell receptors with a tumor-targeting TCR. This process reduces safety risks and should translate to the to improve potency and function versus other technologies for multiplex editing.

Despite recent therapeutic advances delivering improved response rates in subsets of AML, long-term outcomes continue to report with overall 5-year survival below 30%. WT1 is overexpressed in over 90% of AML patients regardless of subtype. And so between our proprietary cell engineering process and the prevalence of this target, we believe NTLA-5001 will be a well-tolerated solution capable of improving long-term outcomes for patients across all mutational subtypes and forms of AML.

We remain on track to submit an IND or equivalent regulatory application for NTLA-5001 midyear. Our first-in-human trial will evaluate the safety and activity of NTLA-5001 in patients with persistent or recurring AML who have previously received first line therapy.

Moving on now to our research programs and platform advancements. We continue to make strides in developing new strategic candidates for genetic diseases and next-generation engineered cell therapies for cancer. The versatility of our approach allows us to move quickly with pipeline expansion, and we remain on track to nominate at least one new development candidate this year.

During the first quarter, we had oral presentations at 2 different scientific conferences, broadening the applications of our modular toolbox. In March, we presented preclinical data introducing our proprietary cytosine deaminase base-editing technology at the Cold Spring Harbor Laboratory scientific meeting on Nucleic Acid Therapies. The data highlights our expansive cell engineering capabilities that enable us to introduce multiple edits via CRISPR as required by next-generation allogeneic cell therapies.

Additionally, at the recent Keystone Genome Editing Meeting, we presented preclinical data extending the modularity of our in vivo delivery studies. Through our extensive LNP discovery and development efforts, we identified a class of LNPs that achieve dose-dependent, therapeutically meaningful editing of bone marrow and hematopoietic stem cells in a preclinical mouse model lasting 1 year following a single dose.

For inherited blood disorders such as sickle cell disease, this approach could greatly reduce the barriers to treatment associated with bone marrow transplantation. More broadly, these results demonstrate the ability to deliver to and edit tissues outside the liver. We will continue to expand upon this work with financial support provided by the Bill & Melinda Gates Foundation.

Although still in the research stage, the technologies shared in this presentation are important demonstrations of our emerging capabilities, which together reflect our commitment to drive our pipeline forward through continuous platform innovation to create potentially curative therapies for patients.

Looking ahead, we plan to share preclinical data at the ASGCT Annual Meeting taking place next week. This will include an update on our research in alpha-1 antitrypsin deficiency, which is the second disease indication for which we have demonstrated robust proof of concept of our targeted in vivo insertion technology to restore normal levels of proteins in on-human primates.

Further, we will be sharing data on our industrialized screening platform utilized to derisk and identify guide RNAs that are both potent and highly specific with no detectable off-target edits. This foundational work has provided us and regulators with key insights and the confidence to move our programs, including NTLA-2001, forward into human clinical trials. We look forward to these presentations next week at ASGCT.

With that, I would like to hand over the call to our CFO, Glenn Goddard, who will provide an overview of our first quarter financial results.

Thank you, Laura, and good morning, everyone. Intellia remains in a strong financial position as we advance our pipeline. Our cash, cash equivalents and marketable securities were $600.8 million as of March 31, 2021, compared to $597.4 million as of December 31, 2020. The increase was mainly driven by $45.3 million of proceeds from the company's at-the-market agreement, $13.3 million in proceeds from employee-based stock plans and $2.4 million from the Regeneron collaboration. These increases were offset in part by cash used to fund operations of approximately $57.6 million.

Our collaboration revenue decreased by $6.5 million to $6.4 million during the first quarter of 2021 compared to $12.9 million during the first quarter of 2020. The decrease was driven by the $5 million milestone payment earned from Novartis for the IND submission of OTQ923 in 2020.

R&D expenses increased by $4.6 million to $39.3 million during the first quarter of 2021 compared to $34.7 million during the first quarter of 2020. This increase was mainly driven by the advancement of our lead programs, research personnel to support these programs and the expansion of our development organization.

G&A expenses increased by $2.3 million to $13.6 million during the first quarter of 2021 compared to $11.3 million during the first quarter of 2020. This increase was related to employee-related expenses, including stock-based compensation of $0.9 million. Finally, we expect our current cash balance to fund operating plans for at least the next 24 months.

And now I will turn the call back over to John for closing remarks.

Thank you, Glenn. As you can see, there are many reasons for excitement for what the remainder of the year holds for our company and the field of genomic medicines.

Our Phase I study of NTLA-2001 is progressing well, and we look forward to sharing interim results mid this year for clinical validation of our platform. We continue to progress our pipeline and expect to file a first-in-human regulatory submission midyear for NTLA-5001. In addition, we expect to submit an IND or IND-equivalent application for NTLA-2002 in the second half of this year. We are advancing our research stage portfolio as we expect to nominate at least one new development candidate this year, and we continue to expand our toolbox to enable the next wave of genomic medicines.

With all this progress, and as we close in on key milestones, we remain focused on our core priorities and wholly committed to making genome editing's promise a reality for patients.

We'll now open the line to any questions. Operator?

(Operator Instructions) Your first question today comes from Salveen Richter with Goldman Sachs.

This is Sonya on for Salveen. We had a few questions on Intellia 2001. So the first is, what data should we expect from the read in mid-'21? How many cohorts should we expect data from? And then the second question is, what is the status of the IND for Intellia 2001 in the U.S.?

Sonya, thanks for the question. Just to remind you, 2001 is a study that we're -- we're currently studying 2001 outside the United States. So for this first-in-human study, there's no plan to have an IND as part of this particular study. The expectation is that for subsequent work, we would come back to the U.S. and have an IND for work that would involve cardiomyopathy in subsequent studies.

With respect to the ongoing study and the data that we anticipate presenting, we're not talking about the number of cohorts other than to say that we progressed well with the study as it was laid out. And we're adhering to the principles that we'll have substantive data that's readily interpretable, and we look forward to sharing that.

Your next question comes from Maury Raycroft with Jefferies.

Congrats on the progress. Just had a question on the 2001 clinical study. Just wondering if there's anything additional you can say on safety so far in the clinical study. I guess one concern in the past is on immunogenicity. And is there anything you could say about that at this point? And will that be part of that the mid-year update?

Thanks, Maury. With respect to safety, I think it's best to look forward to the information that we anticipate sharing here mid this year. The study is progressing, and we're excited with the progress that we've made, and I think we'll address many of your questions at that point in time.

Got it. Okay. And then we've been getting questions, too, on LNP design and, I guess, some of the characteristics that go into your 2 LNPs. And I'm wondering if we could learn more about that in the mid-year update and how your LNPs -- the functionalization translates to an improvement in immunogenicity and also the tunable tropism as well.

Thanks. As the year unfolds, I'm sure there's going to be opportunity to talk more about the platform and the work that we're doing. I think with respect to the clinical data that we're talking about, I would anticipate that most of the discussions at that time will be about the study and the results that we have. But as you know, Maury, as our science progresses, there's points in time where we'd like to share some of the advantages that we have, and there may be opportunities later this year to do that.

Your next question comes from Gena Wang with Barclays.

This is Sheldon on for Gena. So I think you mentioned in the past that the target knockdown level is about at least 80% for the 2001 trial. So right now, you have almost set up the timing of the presentation. Does it mean you already reached the target level in the initial dose level?

The way we've approached this is, as we've said from the outset, that we would share interim data from the studies because if you remember, there's 2 phases to it, the ascending-dose phase and then the expansion phase, where we would take what we think will be the optimal biological dose and study that more fully in a larger set of patients.

The principle that we've applied for this first phase of the study is that we'll have meaningful results that are readily interpretable. We haven't tied that to a specific target for this particular data release. It's true that we set as a benchmark 80% and beyond. Our objective is to surpass 80% because we think the further one reduces the circulating TTR levels, the more beneficial it's going to be for patients. And I think there's places we can look for data that seems to indicate that. So that is our ultimate objective. But the particular data that we share here is not necessarily triggered by any specific number.

The next question comes from Mani Foroohar with SVB Leerink.

This is Rick on the line for Mani. So I actually have a follow-up on Maury's question on safety. And specifically, there are a few novel components being evaluated here for the first time in the clinic. And that's the LNP formulation, the transient expression of Cas9 and guide RNA in the liver and then the actual edits being made to the genome. So I was just hoping to just get your thoughts on if there is any sort of safety signal observed in the trial, what the ability is there to parse out which of those components may be contributing to the signal and potentially read-through for the rest of the in vivo platform.

Yes. So we're talking in general how we think about safety. And the way we approach it is there's the LNP itself and its administration, and then there's the long-term effects of that particular intervention, which we expect to be largely beneficial based on the expected TTR knockouts that we've achieved in animals.

LNPs as a class, you may remember, Rick, generally have a characteristic pattern of safety findings that when one gives sufficient quantities of material, you can trigger all that. We've worked on very, very carefully in our preclinical work to develop a therapeutic index. So the clinical exposures that we're doing in the human trial here is designed to balance the desired and expected TTR effects within the therapeutic index that does not trigger those particular LNP class effects. And the Phase I study is to test exactly that -- those preclinical findings. And as we've said, we'll share some early results here mid this year.

With respect to novel components, I guess the way I think about it is the LNP is largely precedented. Yes, there is a unique piece to it that is the proprietary lipid or cationic lipid. But we think we characterized it very, very well and know very well how it behaves based on preclinical work. And the rest of it is RNA, either guide or mRNA. And again, we think there's really good preclinical models for that.

With respect to the genomic characterization of the effects, that's been extensively addressed preclinically, I would say, more than probably any other drug as far as I'm aware. And I would encourage you to attend the ASGCT Meeting where we're going to go through a lot of how that work is done so you get a really good sense of the completeness and the extent of that effort. So we can maybe revisit after we go through that data later this month.

Your next question comes from Joon Lee with Truist.

You just set your bar at 80%, which is what -- I guess sRNAs and antisense oligos hover around that knockdown level. But as a genome editing tool that is constantly working, do you really need to hit similar knockdown as those antisense oligos or sRNAs to achieve similar clinical efficacy? Or could you envision a situation where you could get less knockdown but still get equivalent or better clinical effect? And could we get clinical data mid-year as well as some of the knockdown levels? And then I have a follow-up question.

So it's a very important question you're asking, which is when we talk about these numbers of knockdown, what does it actually mean, right? And so the numbers are typically presented by some of the other modalities that I'm familiar with at least are typically portrayed as maximal effects. And look, what you're asking is essentially an area under the curve question, which is, well, if you have a maximal effect at particular number, call it, 80%, what is the average effect over time? And one of the advantages of the approach that we're taking here is that the maximal effect is the effect because there's no pharmacokinetic variability that occurs over time.

So our approach to this is we look at 80% as the benchmark. The goal is to surpass it not just on maximal effect but from a sustained effect. And if you go back to some of the preclinical data that we presented, you'll see that when it comes to the animal model, that's exactly what we achieved. So our thesis is that reducing TTR to the lowest possible levels in the blood is going to lead to more clinical benefit, and that's exactly what we're setting out to achieve here. So that's how we think about it.

Okay. So we'll get clinical data along with the knockdown mid-year?

So in the early phase of the study, remember, it's a 3-plus-3 design, and so 4 cohorts. So the extent of clinical data, I think, is going to be very modest here early on. What I would look to is primarily a safety characterization and primarily a TTR effect. There's descriptive clinical data, but the bulk of that information, I would look to the second phase of the study.

Got it. And then one more question. For the vivo genome editing for hematopoietic stem cells, what is the distribution of bone marrow tropic LNP in the liver versus bone marrow? And how does that play into the overall efficacy and durability of this approach for sickle cell disease? And does this take any priority in your overall portfolio strategy given the announcement between CRISPR and Vertex where they seem to be moving aggressively to commercialize it? Or does it not impact your overall strategy? Or do you have something in agreement with Novartis that kind of limits your ability to develop therapeutics for sickle cell disease?

That's a big question with many subparts. I'll tell you how we think about it without going into all the specifics of distribution between liver and bone marrow and various other compartments of the body. Obviously, the objective is to get the right amount to the appropriate cells in the bone marrow. And it's very clear that LNPs as a class have a tendency to be picked up fairly avidly by the liver.

So part of the delivery challenge is addressing the avidity of that clearance that takes place in the liver, and we've made good headway with respect to that. And there's a variety of ways to do that, and our scientists start working on many of them. And it's premature at this point to talk about exactly how we're doing that. But as time unfolds here, I'm sure there will be opportunities to talk more about it.

Just broadly speaking about sickle cell and related disorders of the hematopoietic system, we're very excited by the progress that others have made that show, I think, pretty clearly that one can edit hematopoietic stem cells and treat sickle cell disease pretty effectively. And that's great news for that set of patients who we all know have long suffered with very, very inadequate sorts of therapeutic treatments.

The challenge, however, is that to get to those benefits, one needs to be subjected to a bone marrow transplant, which brings with it significant morbidity and even in some cases, mortality. And so our view is that the final endgame here is avoiding that bone marrow transplant. We know how to edit. It's just getting rid of the bone marrow transplantation.

So our belief is that solving that with an in vivo delivery system, that is what will address the fundamental problem here. So other relationships and other approaches that people take, we admire their work and encourage them to proceed. Our approach is to have something that we think will have the broadest reach and the best solution for the greatest number of patients. And that is what we're working on, and that's what the Gates Foundation has been helping us to do.

Your next question comes from Steven Seedhouse with Raymond James.

I'm surprised to see you guiding to submitting an IND or IND equivalent with your follow-on products. It just seems to imply that either you haven't decided which geography you plan to proceed or that you don't want to say. And I guess I just don't understand why the ambiguity or intrigue is even necessary unless you really don't know and kind of ex U.S. trial is a backup plan at this point. That's basically how it reads to me.

So my question is, I was just hoping you could be clear. Do you actually have plans to file a U.S. IND near term for HAE or AML? Or can you say already right now those will be ex U.S. trials? And if you aren't certain about a U.S. IND still, can you say -- have you had any pre-IND meetings recently? And can you share insights from those interactions?

Well, we're not going to change what we've said, but I thank you for the question. We'll be in a position to give you more clarity as we proceed here. We shared exactly the same guidance with respect to NTLA-2001.

We are very, very engaged in the regulatory interactions. And we've certainly been discussing things with the FDA as well as other regulators, and we're putting ourselves in a position where we can have the broadest base program that gets the most clinical information most efficiently. So I'm not going to be able to address specifically your question, but as time unfolds here, we'll share more information.

The next question comes from Yanan Zhu with Wells Fargo Securities.

A few questions on 2001. First, in terms of the place -- the venue of the medical -- the specific medical meeting, could we -- is it reasonable to assume it is the PNS Meeting in June? And also, could you characterize a little more what you mean by interpretable data? Does that mean data within a certain variability that you could make a judgment of the result? Or could it mean your ability to project some kind of dose response to predict what might happen with additional dosing? Any other around that will be very hopeful.

Thank you. Sure. Thank you. With respect to the particular meeting, we're not sharing that information just yet. However, we won't be surprising people as we get closer to that point in time. We will share in a press release when and where. So people, I think, will have plenty of information in advance to be prepared to attend the meeting or interact with it to get the information.

With respect to interpretable data, that's a principle that we've applied, which really speaks to exactly what you said. With small numbers of patients in an ascending-dose study, one always pays attention to variability if it's there. And one wants to be able to look at those data, see if there's an effect and help make some assessment of what it's likely to mean for not only NTLA-2001 and how it will fit into the pharmacopoeia but also our platform generally. And so those are the principles that we've applied. And I think when we're in a position to share the data, you'll see that we've addressed them.

A quick follow-up. In your EU orphan drug designation application, did the committee ask for clinical data? I think because, obviously, there are chronic therapies, so in some precedents, when multiple -- when there is a standard of care, the committee might ask for data when determining orphan drug status.

Yes. I think the committee, as it makes its determination, asks whether or not there's remaining unmet need. And they concur with the broad-based source of information we get, which includes KOLs patients and treating health care personnel. So it's less about clinical information. It's about the status of the current treatment state of the art.

The next question comes from Silvan Tuerkcan with JMP Securities.

Congrats on all the progress. First, also I wanted to ask about a comment from Laura. Could you just please confirm that you mentioned that you may want to start Intellia 2002 at a higher dose compared to Intellia 2001? And if that is the case, can we read across from that information to Intellia 2001 saying that the first lower dose is probably safe or that it may be too low? And then I have a follow-up.

I'll stand in for Laura here, I guess, just to keep it efficient. But it all goes back to the fundamental premise of modularity. So whether it's on the research side, whether it's on the preclinical side or on the clinical side, what we learned for an LNP and its cargo broadly applies. And so as we collect information from any of those different domains, what we found is that we can apply it to subsequent incarnations of the product and various either regulatory interactions or any clinical interactions.

So the information that we have is -- I'm not going to characterize it other than that it's able to give us some bearing on how we approach 2002, and it may have some utility there.

And my follow-up question is could you have possible redosing in the expansion part of the trial for patients that don't reach the target knockdown levels for some reason. Or is that something you would explore in a later time?

Yes. Broadly based in terms of how to think about the trials, normally, a single ascending-dose study in a single application. There are provisions that we're making in the course of the program, and perhaps in the study, this is work that we're addressing where suboptimal doses, if they occur, those patients may have subsequent recourse to a more active dose. But as that gets clarified, we'll be in a position to talk more about it.

Okay. And maybe one quick last question if I may. Just on big picture, are there any pitfalls that you can point to if we would compare the Intellia 2001 data set to tafamidis or patisiran in terms of time to peak or steady-state knockdown level or patient population? Is there anything you can point us to for this readout to tell us watch out for this or [just maybe going forward]?

So I'm not sure I got the gist of your question. You're asking about tafamidis and knockdown effects versus NTLA-2001? Is that what you asked me?

Yes. When we get the TTR reduction from NTLA-2001, what are some of the straightforward comparisons we can do to the other agents? And what are some of the things to watch out for in terms of stable knockdown levels, et cetera?

Yes. I mean with respect to this particular study, there are exclusions with respect to what other people can take or will have taken ever before coming into the trial. So in terms of measuring any of that in the course of that study directly, that won't be a part of it.

With respect to the behavior of TTR and its decline, I think there'll be a fair amount of information that we would expect to interpret. And one can look at the siRNA material and -- which is the relevant knockdown comparator, I think, TTR levels are not knocked down by tafamidis. So it's a different kind of calculus that one might make. But I think one would expect to have a pretty good set of data to make some broad-based comparisons based on what we're expecting to share.

The next question comes from Jay Olson with Oppenheimer.

For the base editor system that you recently presented, would that base editor be used in both in vivo and ex vivo programs? And how do you plan to integrate that tool into your overall platform?

Yes. Thanks for the question. We're very excited about what particular sorts of applications base editors may be applied to. We see their greatest utility in the ex vivo setting. It's not currently a part of the programs we've been talking about. If you saw the presentation we gave at Cold Spring Harbor, one of the things that we're very mindful of is the state of the art in terms of looking for stochastic off-target effects in the in vivo setting, and that's where we think there's additional work to be done from the field broadly.

So in the nearest term, we think that the ex vivo setting is probably the best place to use the base editor. But I'm sure work will continue, and that may change over time.

Great. And then maybe one follow-on question. Your upcoming presentation at ASGCT, what kind of clinical data should we be looking for? And what are the gating factors to moving that program on to the next steps?

Well, the -- at ASGCT, remember, there's 2 presentations that we're making. One is a very detailed analysis of the off-target approach, which speaks broadly to what we do. So it doesn't relate necessarily to any particular program. The other presentation will be on extended information on the alpha-1 antitrypsin program. We're not talking yet about its status with respect to the pipeline and its candidacy, et cetera. We will have a third presentation where our CSO will also be speaking broadly about gene editing and its clinical utility. So there'll be some other insights. But we won't be talking about any particular development candidates and changing their status.

Your next question comes from Joe Allen with Baird.

It's Jack Allen here. We want to touch briefly on NTLA-2002, and we were wondering if you could talk a bit about your expectations for the trial as you move it towards the clinic. It's our understanding that there are a number of therapies already approved for HAE. How do you expect the magnitude of clinical benefit here as you move it into the clinic?

And then I know someone touched on this earlier, but you briefly mentioned that you may file an IND or IND equivalent for this program by the end of the year. Could you speak to the factors that are going to dictate the decision to go with an IND or an IND equivalent? Is the NTLA-2001 data one of the factors that you're weighing in that decision?

Yes. Just a couple of words about where we think NTLA-2002 can fit in the pharmacopeia. We think that the modality that we have is ideally suited to hereditary angioedema. It's certainly the case that advances have been made with respect to treating that condition. Either patients are treated as an attack occurs, patients don't like that, or they're prophylaxed with ongoing therapy.

Remember, these are patients who are typically identified at the time of puberty or shortly thereafter. So essentially, what you're talking about is lifelong therapy that is a very, very significant treatment burden and one that, in some cases, has become quite effective and others as far less so. So therapeutic opportunity clearly remains.

Don't forget also that most effective therapies are extremely expensive, starting at over $0.5 million a year, with many patients spending over $1 million a year for those same therapies. So whether it's meeting and exceeding the effect that others have achieved or whether it's dealing with the burden of treatment or dealing with a significant pharmacoeconomic cost to the health care system to those patients, we think that we have something to offer in every single front.

With respect to the clinical trial and where we do it, we certainly look across all the work that we do, wherever it is and whatever the drug is and factor in how we think about what we're doing, how we're doing it and where we're going to do it. And we would expect that to be a very central factor in our ultimate decision of where we carry this work out.

There is no time for further questions. I'll now hand back to Lina for closing remarks.

Great. Thank you all for joining us today and for your continued interest and support. We look forward to updating you on our progress. Have a wonderful day.

That does conclude our conference for today. Thank you for participating. You may now disconnect your lines.